In an attempt to strengthen its immuno-oncology pipeline, Gilead Sciences has entered into a collaboration agreement with MacroGenics to develop bispecific antibodies. The alliance, worth up to US$1.7 B, grants Gilead an exclusive option to license MGD024, a Phase I CD123×CD3 drug which leverages MacroGenics’ DART® technology and has the potential to treat various haematologic malignancies. The deal follows MacroGenics’ recent shift to focus on MGD024, instead of its Phase II first-generation CD123×CD3 bispecific, flotetuzumab.